Beth A. Brooke
Known title: DirectorCIK: 0001786769
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
eHealth Partners with BerniePortal and Top Medicare Carrier. eHealth announced new partnerships with BerniePortal and a top Medicare carrier to help employers and brokers manage plan enrollment. These moves aim to expand the company's reach in the insurance market as it prepares for the upcoming annual enrollment period. The stock is currently trading near its 52-week low, with an RSI of 20.4 suggesting it is deeply oversold.
Transaction History
| NYT | ▲ Buy | Grant | 68 | $0 | 7/23/2026 | View on chart |
| EHTH | ▲ Buy | Grant | 61,041 | $0 | 6/18/2026 | View on chart |
| NYT | ▲ Buy | Grant | 2,277 | $0 | 4/22/2026 | View on chart |
| NYT | ▲ Buy | Grant | 54 | $0 | 4/16/2026 | View on chart |
| NYT | ▲ Buy | Grant | 48 | $0 | 1/16/2026 | View on chart |
| NYT | ▲ Buy | Grant | 59 | $0 | 10/23/2025 | View on chart |
| NYT | ▲ Buy | Grant | 65 | $0 | 7/24/2025 | View on chart |
| EHTH | ▲ Buy | Grant | 34,574 | $0 | 6/17/2025 | View on chart |
| NYT | ▲ Buy | Grant | 3,589 | $0 | 4/30/2025 | View on chart |
| NYT | ▲ Buy | Grant | 56 | $0 | 4/17/2025 | View on chart |
| NYT | ▲ Buy | Grant | 37 | $0 | 1/23/2025 | View on chart |
| NYT | ▲ Buy | Grant | 36 | $0 | 10/24/2024 | View on chart |
| EHTH | ▲ Buy | Grant | 18,181 | $0 | 8/7/2024 | View on chart |
| NYT | ▲ Buy | Grant | 36 | $0 | 7/25/2024 | View on chart |
| EHTH | ▲ Buy | Grant | 31,760 | $0 | 6/11/2024 | View on chart |
| NYT | ▲ Buy | Grant | 4,048 | $0 | 4/24/2024 | View on chart |
| NYT | ▲ Buy | Grant | 36 | $0 | 4/18/2024 | View on chart |
| NYT | ▲ Buy | Grant | 26 | $0 | 1/18/2024 | View on chart |
| NYT | ▲ Buy | Grant | 31 | $0 | 10/26/2023 | View on chart |
| NYT | ▲ Buy | Grant | 31 | $0 | 7/27/2023 | View on chart |
| EHTH | ▲ Buy | Grant | 24,446 | $0 | 6/14/2023 | View on chart |
| NYT | ▲ Buy | Grant | 4,472 | $0 | 4/26/2023 | View on chart |
| NYT | ▲ Buy | Grant | 19 | $0 | 4/20/2023 | View on chart |
| NYT | ▲ Buy | Grant | 18 | $0 | 1/19/2023 | View on chart |
| NYT | ▲ Buy | Grant | 21 | $0 | 10/21/2022 | View on chart |
| NYT | ▲ Buy | Grant | 20 | $0 | 7/21/2022 | View on chart |
| EHTH | ▲ Buy | Grant | 16,560 | $0 | 6/15/2022 | View on chart |
| NYT | ▲ Buy | Grant | 3,836 | $0 | 4/27/2022 | View on chart |
| NYT | ▲ Buy | Grant | 6 | $0 | 4/21/2022 | View on chart |
| NYT | ▲ Buy | Grant | 5 | $0 | 1/20/2022 | View on chart |
| NYT | ▲ Buy | Grant | 4 | $0 | 10/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
NYT faces scrutiny over valuation and moat in recent analysis
Recent commentary questions whether The New York Times offers sufficient value compared to other legacy media stocks, noting concerns about its competitive advantage. This skepticism aligns with the stock trading near its 52-week low and below the average analyst target price. The discussion highlights the importance of assessing long-term earnings power in the current market environment.
NYT faces scrutiny over valuation and moat in recent analysis. Recent commentary questions whether The New York Times offers sufficient value compared to other legacy media stocks, noting concerns about its competitive advantage. This skepticism aligns with the stock trading near its 52-week low and below the average analyst target price. The discussion highlights the importance of assessing long-term earnings power in the current market environment.